Bausch Health Q4 Revenue Estimated at $2.7B, EPS Seen at $1.21
Bausch Health’s Q4 2025 revenue is projected at $2.7 billion, representing 5.7% year-over-year growth, while EPS is estimated at $1.21, up 5.2% from a year ago. The company beat consensus twice and missed twice in the last four quarters, with an average negative surprise of 6.3%, and holds a Zacks Rank #3 and Earnings ESP of +0.69%.
1. Q4 2025 Estimates and Growth
Analysts forecast Bausch Health will report revenues of $2.7 billion for Q4 2025, marking a 5.7% increase year-over-year, with earnings per share estimated at $1.21, up 5.2% from Q4 2024. These projections reflect modest top-line gains driven by ongoing demand for the company’s pharmaceutical and eyecare products amid stable market conditions.
2. Earnings Surprise History
In the past four quarters, Bausch Health beat consensus EPS estimates twice and missed twice, delivering an average negative surprise of 6.3%. This mixed track record highlights potential execution risks and the importance of meeting or exceeding estimates to rebuild investor confidence.
3. Zacks Rank and ESP Signal
Bausch Health currently holds a Zacks Rank #3 (Hold) and an Earnings ESP of +0.69%, suggesting slightly higher odds for an earnings beat. The ESP metric indicates recent upward revisions to the short-term EPS outlook, which could signal growing analyst optimism ahead of the February 18 report.
4. Implications for Investors
With consensus estimates reflecting moderate growth and a history of mixed surprises, investors may adopt a cautious stance. Confirmation of consistent beats or upward guidance in the Q4 results could serve as a catalyst, while another miss may intensify downside pressure on the stock.